Final answer:
Cryoprecipitated AHF is used to treat conditions such as hemophilia and Von Willebrand disease by providing necessary clotting factors. It has a long-term storage of one year when frozen, but must be used shortly after thawing to maintain effectiveness. It is not a volume expander, an alternative to whole blood, or restricted to postoperative patients.
Step-by-step explanation:
Cryoprecipitated AHF (Antihemophilic Factor) is a blood product that is rich in clotting factors, including Factor VIII, fibrinogen, von Willebrand factor, Factor XIII, and fibronectin. It is primarily indicated for treatment of conditions such as hemophilia, Von Willebrand disease, and other coagulation abnormalities. Cryoprecipitated AHF is prepared by freezing and then slowly thawing fresh frozen plasma and collecting the resulting precipitate. Its long-term storage in the frozen state can be up to one year. When thawed, it must be used within a short period to ensure its post-preparative stability and to maintain the necessary activity of its components. The freeze-thaw cycle is critical in preserving the clotting factors' integrity for later therapeutic use.
Cryoprecipitated AHF is not used as a volume expander, as an alternative to whole blood, or only in postoperative patients.